Business Description
Sun Biomedical Ltd
ISIN : AU000000SBN6
Description
Dimerix Ltd is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs. The company is developing five product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for COVID-19 pneumonia patients in ICU; DMX-200 for respiratory complications in Covid-19 patients; and DMX-700 for COPD; as well as the proprietary ReceptorHIT assay technology.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 10.37 | |||||
| Equity-to-Asset | 0.11 | |||||
| Debt-to-Equity | 0.83 | |||||
| Debt-to-EBITDA | -0.07 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -20.5 | |||||
| 3-Year EPS without NRI Growth Rate | -17.3 | |||||
| 3-Year FCF Growth Rate | -13 | |||||
| 3-Year Book Growth Rate | -27.3 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.84 | |||||
| Quick Ratio | 4.84 | |||||
| Cash Ratio | 4.76 | |||||
| Days Sales Outstanding | 1169.1 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -24.5 | |||||
| Shareholder Yield % | -2.53 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -14984.21 | |||||
| Net Margin % | -8170.68 | |||||
| ROE % | -260.18 | |||||
| ROA % | -83.17 | |||||
| ROIC % | -711.16 | |||||
| ROC (Joel Greenblatt) % | -239148 | |||||
| ROCE % | -261.49 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 72.5 | |||||
| EV-to-EBIT | -7.33 | |||||
| EV-to-EBITDA | -7.33 | |||||
| EV-to-Revenue | 1097.74 | |||||
| EV-to-FCF | 207.98 | |||||
| Earnings Yield (Greenblatt) % | -13.64 | |||||
| FCF Yield % | 0.44 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sun Biomedical Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | |||
| EPS (TTM) (A$) | 0 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (A$) | 0 | ||
| 20-Day SMA (A$) | 0 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (A$) | 0.01 - 0.01 | ||
| Shares Outstanding (Mil) | 1,323.64 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sun Biomedical Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sun Biomedical Ltd Stock Events
| Event | Date | Price(A$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Sun Biomedical Ltd Frequently Asked Questions
What is Sun Biomedical Ltd(ASX:SBN)'s stock price today?
The current price of ASX:SBN is A$0.00. The 52 week high of ASX:SBN is A$0.01 and 52 week low is A$0.01.
When is next earnings date of Sun Biomedical Ltd(ASX:SBN)?
The next earnings date of Sun Biomedical Ltd(ASX:SBN) is .
Does Sun Biomedical Ltd(ASX:SBN) pay dividends? If so, how much?
Sun Biomedical Ltd(ASX:SBN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers